Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750619 · ClinicalTrials.gov registry record
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
A clinical trial of Gastrointestinal Neoplasms and Benign Neoplasm of Intestinal Tract, sponsored by California Pacific Medical Center Research Institute.
- Recruiting
- Registry status
- 8,000
- Enrollment target
- 1
- Study location
NCT01750619 is a study of Gastrointestinal Neoplasms and Benign Neoplasm of Intestinal Tract that is actively recruiting participants, run by California Pacific Medical Center Research Institute. The registered enrollment target is 8,000 participants, above the 300-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (2567% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01750619, a study of Gastrointestinal Neoplasms and Benign Neoplasm of Intestinal Tract, is actively recruiting participants, sponsored by California Pacific Medical Center Research Institute.
- RECRUITING
- Registry status
- 8,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate clinical outcome for patients receiving treatment of suspected premalignant and malignant gastrointestinal lesions at Interventional Endoscopy Services. The primary outcome is curative endoscopic resection. Secondary outcomes include resection technique utilized, rates of en bloc resection and adverse event rates, including infection, bleeding, perforation and death, and one-year survival rates.
Conditions Studied
Study Locations (1)
California
- Interventional Endoscopy Services - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2011-07 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750619
The ClinicalTrials.gov registry entry for NCT01750619 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 300-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (2567% higher). The listed sponsor is California Pacific Medical Center Research Institute, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT01750619 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01750619 about?
NCT01750619 is a clinical study titled "Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions". To evaluate clinical outcome for patients receiving treatment of suspected premalignant and malignant gastrointestinal lesions at Interventional Endoscopy Services. The primary outcome is curative endoscopic resection. Secondary outcomes include resection technique utilized, rates of en bloc resecti...
What is the current status of trial NCT01750619?
This trial is currently recruiting. The enrollment target is 8,000 participants. The study started on 2011-07. Estimated completion is 2030-12.
What conditions does trial NCT01750619 study?
This clinical trial studies the following conditions: Gastrointestinal Neoplasms, Benign Neoplasm of Intestinal Tract.
Who is sponsoring clinical trial NCT01750619?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01750619 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RECRUITING · Phase 3
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
RECRUITING · Phase 1
-
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
RECRUITING · Phase 1
Explore more on PlainTrial
Gastrointestinal Neoplasms
All registered trials for this condition
Benign Neoplasm of Intestinal Tract
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.